Skip to main content
Premium Trial:

Request an Annual Quote

Bank Lowers Estimate, Valuation on Illumina's Stock

NEW YORK (GenomeWeb News) – Leerink Swann analyst Isaac Ro today lowered the bank's estimates and valuation on Illumina.

He lowered the estimate on Illumina's 2010 earnings per share to $1.03 from his previous estimate of $1.18, based on the assumption that the firm's R&D and SG&A spending will increase.

While Ro described the near-term sentiment for the stock as negative, he wrote that 2010 should be a "catalyst-rich year," re-focusing investors on the firm's product pipeline. "In our opinion, management has repeatedly demonstrated vigilance and activism around new technology development and will continue to do so via M&A," he wrote.

Ro maintained an "outperform" rating on Illumina's stock, but he lowered the 12-month valuation to $28-$30 from a previous range of $35-$38.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.